Attar Alain
Service d'Hépato-Gastroentérologie et d'Assistance Nutritive, Hôpital Lariboisière, 2, rue Ambroise-Paré, 75475 Paris Cedex 10, France.
Ann Med Interne (Paris). 2002 Jun;153(4):260-4.
Gastrointestinal involvement occurs in most patients with systemic sclerosis. Pathology is characterized by vasculopathy, resulting in tissue ischemia, progressive dysfunction and fibrosis. In its diffuse and visceral pattern, digestive manifestations may involve most of the intestinal tract and are the most frequent before renal, cardiac and pulmonary involvement. Whatever the visceral extension, about 80% of patients have digestive manifestations including gastroesophageal reflux, abnormalities of intestinal motility leading to chronic intestinal pseudo-obstruction and small bowel bacterial overgrowth and malnutrition. Long-term treatment of reflux with high-dose proton pump inhibitors appears safe and effective for symptom relief and may prevent recurrence of esophagitis and stricture. Prokinetic agents effective in pseudoobstruction include metoclopramide, domperidone, octreotide, and erythromycin.
大多数系统性硬化症患者会出现胃肠道受累。病理学特征为血管病变,导致组织缺血、进行性功能障碍和纤维化。在弥漫性内脏型中,消化系统表现可能累及大部分肠道,且在肾脏、心脏和肺部受累之前最为常见。无论内脏受累范围如何,约80%的患者有消化系统表现,包括胃食管反流、导致慢性假性肠梗阻的肠道动力异常、小肠细菌过度生长和营养不良。大剂量质子泵抑制剂长期治疗反流对缓解症状似乎安全有效,且可能预防食管炎和狭窄的复发。对假性肠梗阻有效的促动力药物包括甲氧氯普胺、多潘立酮、奥曲肽和红霉素。